Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 19 (2) , e135-e147
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: adjusting for the burden of ensuing chronic kidney diseaseCanadian Urological Association Journal, 2013
- A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder CancerEuropean Urology, 2012
- Using QALYs in CancerPharmacoEconomics, 2011
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapyCancer, 2010
- Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinomaCancer, 2010
- The Half-Cycle Correction Explained: Two Alternative Pedagogical ApproachesMedical Decision Making, 2008
- Optimal Management of High-Risk T1G3 Bladder Cancer: A Decision AnalysisPLOS Medicine, 2007
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003